GlassScriptPhysician profile
Angela Ray
NPI 1437861861
$4,013.87
in general payments reported to CMS, 2019-2025
25 companies · $1,476 in 2025
The $1,476 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $989 · 2024: $1,549 · 2025: $1,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,843 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,843.27 |
| Education | $170.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $645.04 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $622.50 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $622.21 | 2023-2025 | Xifaxan, Trulance |
| Pfizer INC. | $352.95 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $244.48 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $191.71 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $178.78 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $152.34 | 2023-2025 | |
| Qol Medical, LLC | $149.59 | 2023-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $146.37 | 2024-2025 | Zenpep, Vowst |
| Ironwood Pharmaceuticals, INC | $86.11 | 2023-2024 | Linzess |
| Abbvie INC. | $85.94 | 2024-2025 | |
| Evoke Pharma, INC. | $81.75 | 2024-2025 | |
| Mirum Pharmaceuticals, INC. | $68.67 | 2025 | Livmarli, Chenodal, Cholbam |
| Gilead Sciences, INC. | $50.79 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $45.09 | 2023 | Stelara |
| Regeneron Healthcare Solutions, INC. | $44.80 | 2024 | Dupixent |
| Nestle Healthcare Nutrition INC. | $40.90 | 2023 | |
| Intercept Pharmaceuticals, INC. | $37.84 | 2023-2024 | Ocaliva |
| Celltrion USA INC. | $34.66 | 2023-2024 | Zymfentra, Yuflyma |
| Ferring Pharmaceuticals INC. | $30.61 | 2023-2024 | Rebyota |
| Fresenius Kabi USA, LLC | $29.92 | 2023 | Idacio |
| Novo Nordisk INC | $27.15 | 2023 | Wegovy |
| Daiichi Sankyo INC. | $22.15 | 2025 | Injectafer |
| Albireo Pharma, INC. | $21.52 | 2024 | Bylvay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.